AR095264A1 - Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 - Google Patents
Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3Info
- Publication number
- AR095264A1 AR095264A1 ARP140100876A ARP140100876A AR095264A1 AR 095264 A1 AR095264 A1 AR 095264A1 AR P140100876 A ARP140100876 A AR P140100876A AR P140100876 A ARP140100876 A AR P140100876A AR 095264 A1 AR095264 A1 AR 095264A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- fluorinated
- alkoxy
- group
- radicals
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuestos de acilaminocicloalquilo de fórmula (1) que son como se describe en la presente, sus sales y sus N-óxidos, que presentan propiedades terapéuticas valiosas y que resultan particularmente apropiados para tratar aquellas enfermedades que responden a la modulación del receptor de dopamina D3. Reivindicación 1: Un compuesto caracterizado porque es de la fórmula (1) donde m es 1 ó 2; n es 1 ó 2; A se selecciona entre el grupo que consiste en CH₂, CH₂CH₂, CHFCH₂ y CF₂CH₂; R¹ es un radical cíclico que contiene oxígeno seleccionado entre oxetanilo, oxetanilo fluorado, oxolanilo, oxolanilo fluorado, cicloalquilo C₃₋₆, que tiene uno o dos radicales que contienen oxígeno seleccionados entre el grupo que consiste en OH, alcoxi C₁₋₂, alcoxi C₁₋₂ fluorado, y un oxígeno de carbonilo, y que adicionalmente puede tener 1 ó 2 radicales seleccionados entre flúor, alquilo C₁₋₂ y alquilo C₁₋₂ fluorado; R² se selecciona entre el grupo que consiste en hidrógeno y flúor; R³ᵃ se selecciona entre el grupo que consiste en hidrógeno y metilo; R³ᵇ se selecciona entre el grupo que consiste en hidrógeno y metilo; R⁴ es alquilo C₄₋₆ ramificado o alquilo C₄₋₆ fluorado ramificado; y R⁵ se selecciona entre el grupo que consiste en alquilo C₁₋₆, alquilo C₁₋₃ fluorado, alcoxi C₁₋₂-alquilo C₁₋₄, alcoxi C₁₋₂-alquilo C₁₋₄ fluorado, hidroxi-alquilo C₁₋₄, hidroxi-alquilo C₁₋₄ fluorado, oxetanilo, oxetanilo fluorado, oxolanilo, oxolanilo fluorado, cicloalquilo C₃₋₅, cicloalquilo C₃₋₅ fluorado, cicloalquil C₃₋₅-alquilo C₁₋₄, cicloalquil C₃₋₅-alquilo C₁₋₄ fluorado, cicloalcoxi C₃₋₅-alquilo C₁₋₄ y cicloalcoxi C₃₋₅-alquilo C₁₋₄ fluorado, donde la unidad cicloalquilo en los últimos seis grupos de radicales mencionados puede tener 1 ó 2 radicales seleccionados entre hidroxilo, alcoxi C₁₋₂, alcoxi C₁₋₂ fluorado, alquilo C₁₋₂ y alquilo C₁₋₂ fluorado, donde la unidad cicloalcoxi en los últimos dos radicales mencionados puede tener 1 ó 2 radicales seleccionados entre hidroxilo, alcoxi C₁₋₂, alcoxi C₁₋₂ fluorado, alquilo C₁₋₂ y alquilo C₁₋₂ fluorado; los N-óxidos, las prodrogas y las sales farmacéuticamente aceptables de estos compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361786869P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095264A1 true AR095264A1 (es) | 2015-09-30 |
Family
ID=51529958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100876A AR095264A1 (es) | 2013-03-15 | 2014-03-12 | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US9388141B2 (es) |
| AR (1) | AR095264A1 (es) |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10311065A1 (de) | 2003-03-13 | 2004-09-23 | Abbott Gmbh & Co. Kg | Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung |
| JP2004359689A (ja) | 2003-06-05 | 2004-12-24 | Abbott Gmbh & Co Kg | ドーパミンｄ３受容体のモジュレーションに反応する障害の治療に適するトリアゾール化合物 |
| DE102004027358A1 (de) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyrimidinverbindungen und ihre Verwendung |
| DE102004027359A1 (de) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyridin-2-onverbindungen und deren Verwendung |
| WO2006015842A1 (en) | 2004-08-09 | 2006-02-16 | Abbott Gmbh & Co. Kg | 4-piperazinyl-pyrimidine compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| DE102004061593A1 (de) | 2004-12-21 | 2006-06-22 | Abbott Gmbh & Co. Kg | Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung |
| HUP0500170A3 (en) | 2005-02-03 | 2007-11-28 | Richter Gedeon Nyrt | Piperazine derivatives, process for producing them and pharmaceutical compositions containing them |
| EP1870405A1 (en) | 2006-06-22 | 2007-12-26 | Bioprojet | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands |
| WO2008065500A2 (en) * | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Heteroaryl amides as type i glycine transport inhibitors |
| JP2010531837A (ja) * | 2007-07-02 | 2010-09-30 | エフ．ホフマン−ラ ロシュ アーゲー | 微量アミン関連レセプター（ｔａａｒ）に対して良好な親和性を有する２−イミダゾリン |
| PA8802101A1 (es) | 2007-11-02 | 2009-08-26 | Abbott Gmbh & Co Kg | Compuestos de 1,2,4-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina d3 |
| US7875610B2 (en) | 2007-12-03 | 2011-01-25 | Richter Gedeon Nyrt. | Pyrimidinyl-piperazines useful as D3/D2 receptor ligands |
| WO2010034648A1 (en) | 2008-09-23 | 2010-04-01 | F. Hoffmann-La Roche Ag | Pyridinylpiperazin derivatives useful as modulators of dopamine d3 receptors |
| US8586579B2 (en) | 2010-06-21 | 2013-11-19 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
| US8470828B2 (en) | 2010-07-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
| US9376396B2 (en) | 2012-10-22 | 2016-06-28 | AbbVie Deutschland GmbH & Co. KG | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor |
| UY35420A (es) | 2013-03-15 | 2014-10-31 | Abbvie Inc | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
-
2014
- 2014-03-12 AR ARP140100876A patent/AR095264A1/es unknown
- 2014-03-14 US US14/213,720 patent/US9388141B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9388141B2 (en) | 2016-07-12 |
| US20140275104A1 (en) | 2014-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2016000041A (es) | Compuestos derivados de 5,5,7,7-tetrametil-5,7-dihidro-4h-tieno[2,3-c]piran-3-carboxamida que son moduladores del regulador de la conductancia transmembrana de la fibrosis quística (cftr) | |
| AR093099A1 (es) | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3 | |
| UY35420A (es) | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 | |
| CY1119707T1 (el) | Ενωσεις διαρυλικου αμιδιου ως αναστολεις της κινασης | |
| ECSP14013188A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a | |
| NI201400043A (es) | 4 - fenil - piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| BR112017003658A2 (pt) | composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica. | |
| MX2016014308A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7. | |
| MX2017006382A (es) | Analogos de eter fosfolipidico como portadores de farmacos dirigidos a cancer. | |
| NI201700056A (es) | 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer | |
| CR20160321A (es) | Modulares de tetrahidropiridopirazinas de gpr6 | |
| NZ724792A (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| CU20160120A7 (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| PH12014502413A1 (en) | Cyclic bridgehead ether dgat1 inhibitors | |
| CR20150571A (es) | Compuestos y composiciones terapéuticos | |
| BR112015001502A2 (pt) | derivados de tipo azaindazol ou diazaindazol para tratamento de dor | |
| NZ707778A (en) | Therapeutic compounds and compositions and their use as pkm2 modulators | |
| ECSP18012103A (es) | Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r) | |
| CU20190069A7 (es) | Compuestos químicos derivados sustituidos de 1h-pirrolo[2,3-b] piridina como moduladores del receptor de hidrocarburos de arilo (ahr) | |
| AR088983A1 (es) | Procedimiento para la preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas | |
| BR112016017747A2 (pt) | Agente de intensificação de efeito de reabilitação pós lesão de nervo compreendendo derivados de éter de alquila ou sal do mesmo | |
| UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
| CU20170007A7 (es) | Compuestos de imidazopiridazina | |
| BR112017011883A2 (pt) | composição de organosiloxano com alto índice de refração e aplicações contendo a mesma | |
| PE20151669A1 (es) | Compuestos de azetidiniloxifenilpirrolidina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |